Adj. EBITA SEK 57m, 6% below ABGSCe SEK 61m* Organic growth softer than expected* Consensus adj. EBITA revisions likely down ...
Sales were SEK 2,751m (+6% vs. ABGSCe), -8% y-o-y* Order intake decreased 9% y-o-y to SEK 2,706m* We expect cons to lift '27e ...
Net sales SEK 616m, -1% vs ABGSCe and Factset cons.* EBITA SEK 83m, -6% vs ABGSCe, -4% vs cons* Report moves cons. '26e EBITA ...
Xvivo Perfusion (Q3 Initial take): Strong sales growth, boosted by Thoracic - Redeye ...
Q3 sales 6% above our ests. at SEK 260m, for 20% org. growth* EBITA SEK 27m vs. ABGSCe 20m* Trading at 9x-7x '27e-'28e ...
Sequential sales decline, but order activity has improved* We lift '26e/'27e/'28e EBIT by 9%/7%/6%* 14-11x '26e-'27e EV/EBIT ...
Q3e sales +6%, with 5% organic growth* Raised EBITA driven by new contracts* Share trading at 15x '26e EV/EBITA, goes to 9x ...
Q3e: sequential step-up in organic growth and margin* M&A the main driver behind our EBITA upgrades* Two new acquisitions end ...
ATOSS will release preliminary Q3 figures on Friday. We expect another strong quarter, which should make the margin guidance ...
We lower total ‘27e-‘28e sales by 4%, see break-even in FY'27e* Recycling +66% y-o-y, record trial activity and growing ...
Demand stabilising, but reduction in FTEs a headwind* We cut adj. EBITA by 6% for '26e and 10% for '27e* Trading at ...
Nyheter, eventinbjudningar och erbjudanden från samarbetspartners – direkt till din inkorg. Jag samtycker till att skriva upp min e-postadress för att få regelbundna nyhetsbrev som också innehåller ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results